

**FINANCIAL STATEMENTS (Unaudited)**  
**For the period from 01.07.2024 to 31.03.2025**



**THE IBN SINA PHARMACEUTICAL INDUSTRY PLC**

Tanin Center, 3 Asad Gate, Mirpur Road, Mohammadpur,  
Dhaka-1207, Bangladesh.

**THE IBN SINA PHARMACEUTICAL INDUSTRY PLC**  
**CONSOLIDATED STATEMENT OF FINANCIAL POSITION (Unaudited)**  
**As at 31 March 2025**

		Amount in Taka	
		31 March 2025	30 June 2024
<b>ASSETS:</b>			
<b>Non-Current Assets:</b>		<b>4,458,658,520</b>	<b>3,888,791,104</b>
Property, Plant and Equipment	04.A	2,559,686,790	2,628,798,080
Capital Work-In-Progress	05.A	1,797,160,666	1,138,897,211
Right-of-Use Assets	05.B	39,273,845	57,877,245
Advances, Deposits & Prepayments	10.A.1	11,911,000	9,048,009
Financial Assets	06.A	50,626,219	54,170,559
<b>Current Assets :</b>		<b>2,792,890,291</b>	<b>2,620,323,446</b>
Financial Assets	7.B	22,500,000	166,791,561
Inventories	08.A	1,703,135,821	1,585,350,954
Trade and Other Receivables	09.A	239,500,348	202,514,000
Advances, Deposits & Prepayments	10.A	433,969,479	300,437,038
Cash & Cash Equivalents	11.A	393,784,643	365,229,893
<b>TOTAL ASSETS</b>		<b>7,251,548,810</b>	<b>6,509,114,550</b>
<b>SHAREHOLDERS' EQUITY AND LIABILITIES:</b>			
<b>Equity attributable to the owners of the company:</b>		<b>3,766,263,595</b>	<b>3,497,480,774</b>
Share Capital	12	312,436,270	312,436,270
Tax Holiday Reserve	13	4,392,110	4,392,110
FVOCI Reserve	14	(11,972,500)	(8,610,720)
Retained Earnings	15.A	3,461,407,715	3,189,263,114
<b>Non Controlling Interests</b>	15.B	<b>71,266,863</b>	<b>35,879,719</b>
<b>LIABILITIES:</b>			
<b>Non-Current Liabilities:</b>		<b>1,055,219,157</b>	<b>657,654,586</b>
Long Term Finance	16.A	921,308,872	530,490,522
Employee Benefit Obligations	17.A	1,541,993	1,185,180
Lease Liabilities	17.B	14,715,684	24,798,698
Deferred Tax Liabilities	19	117,652,608	101,180,185
<b>Current Liabilities:</b>		<b>2,358,799,195</b>	<b>2,318,099,470</b>
Short Term Finance	20.A	844,862,323	1,242,553,919
Current Portion of Long Term Finance	21	46,726,327	62,301,769
Lease Liabilities	17.B	16,840,388	25,538,281
Trade and Other Payable	22.A	946,830,160	663,984,345
Unclaimed Dividend	22.B	57,827,610	39,140,597
Income Tax Payables	23.A	445,712,387	284,580,559
<b>TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES</b>		<b>7,251,548,810</b>	<b>6,509,114,550</b>
<b>Net Assets Value (NAV) Per Share</b>	31.A	<b>120.55</b>	<b>111.94</b>

  
Chief Financial Officer

  
Company Secretary

  
Director, Finance

Dated, Dhaka .  
28 April 2025

  
Managing Director


  
Chairman



**THE IBN SINA PHARMACEUTICAL INDUSTRY PLC**  
**CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (Unaudited)**

For the period from 1 July 2024 to 31 March 2025

Amount in Taka				
Notes	1 July 2024 to 31 March 2025	1 July 2023 to 31 March 2024	1 January 2025 to 31 March 2025	1 January 2024 to 31 March 2024
<b>REVENUE</b>				
24.A	8,813,387,803	8,379,866,298	2,883,341,512	2,554,040,173
24.C	(5,280,430,823)	(5,025,750,492)	(1,746,401,994)	(1,555,241,054)
<b>GROSS PROFIT</b>	<b>3,532,956,979</b>	<b>3,354,115,806</b>	<b>1,136,939,517</b>	<b>998,799,119</b>
<b>OPERATING EXPENSES</b>	<b>(2,808,179,990)</b>	<b>(2,620,798,399)</b>	<b>(877,273,371)</b>	<b>(803,251,487)</b>
Administrative expenses	25.A	(205,598,166)	(177,308,649)	(71,483,147)
Selling and Distribution expenses	26.A	(2,602,581,825)	(2,443,489,750)	(805,790,225)
<b>OPERATING PROFIT</b>	<b>724,776,989</b>	<b>733,317,407</b>	<b>259,666,146</b>	<b>195,547,632</b>
Finance charges	34.A	(59,673,370)	(37,603,775)	(20,919,747)
Other income		16,129,017	13,626,787	4,400,369
<b>Profit before WPPF and welfare fund</b>	<b>681,232,637</b>	<b>709,340,419</b>	<b>243,146,769</b>	<b>186,012,998</b>
Workers' P.P. fund and welfare fund	27.A	(34,635,324)	(34,226,940)	(9,344,517)
<b>PROFIT BEFORE TAX</b>	<b>646,597,313</b>	<b>675,113,479</b>	<b>233,802,252</b>	<b>176,881,351</b>
Income tax expenses	28.A	(177,230,718)	(167,958,388)	(60,302,842)
<b>PROFIT FOR THE PERIOD</b>	<b>469,366,595</b>	<b>507,155,091</b>	<b>173,499,410</b>	<b>134,690,718</b>
<b>PROFIT /(LOSS) ATTRIBUTABLE TO:</b>				
Owners of the Company	468,979,451	506,673,598	173,571,500	134,550,635
Non-controlling interest	387,144	481,493	(72,090)	140,082
	<b>469,366,595</b>	<b>507,155,091</b>	<b>173,499,410</b>	<b>134,690,717</b>
<b>Other Comprehensive Income:</b>				
Change in fair value of Marketable Securities	29	(3,735,311)	(5,376,463)	(678,849)
Less: Deferred tax		(373,531)	(537,646)	(67,885)
Total other comprehensive income for the period, net of tax		(3,361,780)	(4,838,816)	(610,964)
<b>Total Comprehensive Income for the period</b>	<b>466,004,815</b>	<b>502,316,275</b>	<b>172,888,446</b>	<b>129,888,982</b>
<b>Total Comprehensive income Attributable to:</b>				
Owner of the Company	465,617,671	501,834,782	172,960,536	129,748,899
Non-controlling interest	387,144	481,493	(72,090)	140,082
	<b>466,004,815</b>	<b>502,316,275</b>	<b>172,888,446</b>	<b>129,888,981</b>
<b>Earnings Per Share (EPS)</b>	<b>30.A</b>	<b>15.02</b>	<b>16.23</b>	<b>5.55</b>
<b>Number of Shares used to Compute EPS</b>	<b>31,243,627</b>	<b>31,243,627</b>	<b>31,243,627</b>	<b>31,243,627</b>


  
Chief Financial Officer

  
Company Secretary

  
Director, Finance

Dated, Dhaka .  
28 April 2025

  
Managing Director

  
Chairman

**THE IBN SINA PHARMACEUTICAL INDUSTRY PLC**  
**CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (Unaudited)**  
For the period from 1 July 2024 to 31 March 2025


Amount in Taka						
Particulars	Paid up Capital	Tax Holiday Reserve	FVOCI Reserve	Retained Earnings	Non Controlling Interest	Total
<b>Balance as at 1 July 2023</b>	312,436,270	4,392,110	(2,266,352)	2,706,202,754	35,051,367	3,055,816,151
Statement of profit or loss and other Comprehensive Income for period ended 30 June 2024			(6,344,369)	670,522,122	828,351	665,006,104
Dividend for the year 30 June 2023 (Cash-60%)				(187,461,762)		(187,461,762)
Issued during the year					-	-
<b>Balance as at 30 June 2024</b>	312,436,270	4,392,110	(8,610,721)	3,189,263,114	35,879,718	3,533,360,493
Statement of profit or loss and other Comprehensive Income for period ended 31 March, 2025			(3,361,780)	468,979,451	387,144	466,004,815
Dividend for the year 30 June, 2024 (Cash-60%)				(196,834,850)		(196,834,850)
Issued during the year					35,000,000	35,000,000
<b>Balance as at 31 March 2025</b>	312,436,270	4,392,110	(11,972,501)	3,461,407,715	71,266,862	3,837,530,458

**STATEMENT OF CHANGES IN EQUITY (Unaudited)**  
For the period from 1 July 2023 to 31 March 2024

Amount in Taka						
Particulars	Paid up Capital	Tax Holiday Reserve	FVOCI Reserve	Retained Earnings	Non Controlling Interest	Total
<b>Balance as at 1 July 2022</b>	312,436,270	4,392,110	(685,588)	2,288,247,972	20,659,192	2,625,049,957
Statement of profit or loss and other Comprehensive Income for period ended 30 June 2023			(1,580,764)	605,416,544	392,175	604,227,956
Dividend for the year 30 June 2022 (Cash-60%)				(187,461,762)		(187,461,762)
Issue during the year					14,000,000	14,000,000
<b>Balance as at 30 June 2023</b>	312,436,270	4,392,110	(2,266,352)	2,706,202,754	35,051,368	3,055,816,151
Statement of profit or loss and other Comprehensive Income for period ended 31 March 2024			(4,838,816)	506,673,598	481,493	502,316,275
Dividend for the year 30 June, 2023 (Cash-60%)				(187,461,762)		(187,461,762)
<b>Balance as at 31 March 2024</b>	312,436,270	4,392,110	(7,105,168)	3,025,414,590	35,532,861	3,370,670,664

  
Chief Financial Officer

  
Company Secretary

  
Director, Finance

  
Managing Director

  
Chairman

Dated, Dhaka .  
28 April 2025



**THE IBN SINA PHARMACEUTICAL INDUSTRY PLC**  
**CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited)**  
For the period from 1 July 2024 to 31 March 2025

	Amount in Taka	
	01 July 2024 to 31 March 2025	01 July 2023 to 31 March 2024
<b>Cash Flows From Operating Activities:</b>		
Received from revenue and others	8,801,401,455	8,308,070,708
Payment for operation, expenses & others	(7,807,221,620)	(7,665,717,223)
Miscellaneous income	939,011	677,721
<b>Cash generated from operations</b>	<b>995,118,846</b>	<b>643,031,206</b>
Income tax paid	(121,071,080)	(125,790,465)
Payment for Financial charges	(56,685,494)	(33,060,710)
<b>Net cash provided by operating activities</b>	<b>817,362,271</b>	<b>484,180,030</b>
<b>Cash Flows From Investing Activities:</b>		
Acquisition of property, plant and equipment	(653,186,915)	(784,718,945)
Proceeds from sale of property, plant equipment	-	359,793
Dividend Received/ IBBL-MPB	-	198,750
Acquisition of financial assets	70,544,340	(62,967,634)
Received from bank	5,430,918	3,624,203
<b>Net cash used in investing activities</b>	<b>(577,211,657)</b>	<b>(843,503,832)</b>
<b>Cash Flows From Financing Activities:</b>		
Payment of dividend	(178,147,838)	(154,173,401)
Payment of lease liabilities	(22,038,783)	(20,997,420)
Received from Non Controlling Interests	10,000,000	-
Long term finance received/(paid) from bank (Net)	390,818,350	102,183,343
Short term finance received/(paid) from bank (Net)	(413,267,038)	527,809,051
<b>Net cash used in financing activities</b>	<b>(212,635,308)</b>	<b>454,821,573</b>
Increase/(decrease) in cash and cash equivalents	27,515,306	95,497,771
Cash and cash equivalents at 1 July	365,229,893	232,227,915
Foreign Exchange Fluctuation Gain/(Loss) on FCAD ERQ Accounts	1,039,444	1,576,458
<b>Cash and cash equivalents at 31 March</b>	<b>393,784,643</b>	<b>329,302,144</b>
<b>NOCFPS ( Note 32.A)</b>	<b>26.16</b>	<b>15.50</b>

**Non Controlling Interests**

  
Chief Financial Officer

  
Company Secretary

  
Director, Finance

Dated, Dhaka .  
28 April 2025

  
Managing Director

  
Chairman


# THE IBN SINA PHARMACEUTICAL INDUSTRY PLC


## STATEMENT OF FINANCIAL POSITION (Unaudited)

As at 31 March 2025

		Amount in Taka	
		31 March 2025	30 June 2024
<b>ASSETS:</b>			
<b>Non-Current Assets:</b>			
Property, Plant and Equipment	04	4,478,045,084	3,927,192,582
Capital Work-In-Progress	05	2,331,581,338	2,402,132,734
Right-of-Use Assets	05.B	1,085,733,211	580,044,566
Financial Assets	06	39,273,845	57,877,245
Advances, Deposits & Prepayments	10.1.A	21,626,219	25,170,559
Investment in Subsidiaries	07	11,661,000	8,798,009
		988,169,470	853,169,470
<b>Current Assets :</b>		<b>2,294,909,312</b>	<b>2,150,287,884</b>
Financial Assets	07.A	22,500,000	89,500,000
Inventories	08	1,476,658,910	1,338,777,834
Trade and Other Receivables	09	199,853,742	167,308,708
Advances, Deposits & Prepayments	10.1	363,919,830	242,225,497
Cash & Cash Equivalents	11	231,976,830	312,475,845
<b>TOTAL ASSETS</b>		<b>6,772,954,395</b>	<b>6,077,480,466</b>
<b>SHAREHOLDERS' EQUITY AND LIABILITIES:</b>			
<b>Shareholders' Equity:</b>			
Share Capital	12	3,797,364,950	3,475,989,493
Tax Holiday Reserve	13	312,436,270	312,436,270
FVOCI Reserve	14	4,392,110	4,392,110
Retained Earnings	15	(11,972,500)	(8,610,720)
		3,492,509,070	3,167,771,833
<b>LIABILITIES:</b>			
<b>Non-Current Liabilities:</b>			
Long Term Finance	16	829,128,636	534,277,576
Employee Benefit Obligations	17	697,333,817	409,007,995
Lease Liabilities	17.B	1,541,993	1,185,181
Deferred Tax Liabilities	18	14,715,684	24,798,698
		115,537,142	99,285,702
<b>Current Liabilities:</b>		<b>2,146,460,809</b>	<b>2,067,213,397</b>
Short Term Finance	20	826,862,322	1,122,170,475
Current Portion of Long Term Finance	21	46,726,327	62,301,769
Lease Liabilities	17.B	16,840,388	25,538,281
Trade and Other Payables	22	787,081,273	562,195,866
Unclaimed Dividend	22.B	57,827,610	39,140,597
Income Tax Payables	23	411,122,889	255,866,409
<b>TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES</b>		<b>6,772,954,395</b>	<b>6,077,480,466</b>
<b>Net Assets Value (NAV) Per Share</b>		<b>121.54</b>	<b>111.25</b>

  
Chief Financial Officer

  
Company Secretary

  
Director, Finance

Dated, Dhaka .  
28 April 2025

  
Managing Director

  
Chairman



**THE IBN SINA PHARMACEUTICAL INDUSTRY PLC**  
**STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (Unaudited)**

For the period from 1 July 2024 to 31 March 2025

					Amount in Taka
	Notes	1 July 2024 to 31 March 2025	1 July 2023 to 31 March 2024	1 January 2025 to 31 March 2025	1 January 2024 to 31 March 2024
REVENUE	24	7,995,902,307	7,448,881,922	2,585,983,653	2,285,756,508
Cost of goods sold	24.B	(4,793,671,477)	(4,477,426,167)	(1,569,924,874)	(1,383,683,291)
GROSS PROFIT		3,202,230,829	2,971,455,755	1,016,058,778	902,073,217
OPERATING EXPENSES		(2,427,697,936)	(2,259,233,175)	(775,770,514)	(706,283,725)
Administrative expenses	25	(174,102,198)	(153,098,714)	(61,453,447)	(41,549,793)
Selling & Distribution expenses	26	(2,253,595,738)	(2,106,134,460)	(714,317,067)	(664,733,932)
OPERATING PROFIT		774,532,893	712,222,580	240,288,264	195,789,491
Finance charges	34	(59,673,370)	(37,603,775)	(20,919,747)	(13,839,841)
Other income		12,482,276	10,475,999	4,116,175	3,393,818
Profit before WPPF and welfare fund		727,341,800	685,094,804	223,484,693	185,343,468
Workers' P.P. fund and welfare fund	27	(34,635,324)	(32,623,562)	(10,642,128)	(8,825,879)
PROFIT BEFORE TAX		692,706,476	652,471,242	212,842,565	176,517,589
Income tax expenses	28	(171,134,388)	(157,487,927)	(58,197,975)	(40,001,331)
PROFIT FOR THE PERIOD		521,572,088	494,983,315	154,644,590	136,516,258
Other Comprehensive Income:					
Change in fair value of Marketable Securities	29	(3,735,311)	(5,376,463)	(678,849)	(5,335,263)
Less: Deferred tax		(373,531)	(537,646)	(67,885)	(533,526)
Total other comprehensive income for the period, net of tax		(3,361,780)	(4,838,816)	(610,964)	(4,801,736)
Total Comprehensive Income for the period		518,210,308	490,144,499	154,033,626	131,714,521
Earnings Per Share (EPS)	30	16.69	15.84	4.93	4.22
Number of Shares used to Compute EPS		31,243,627	31,243,627	31,243,627	31,243,627

  
Chief Financial Officer

  
Company Secretary

  
Director, Finance

Dated, Dhaka .  
28 April 2025

  
Managing Director

  
Chairman

**THE IBN SINA PHARMACEUTICAL INDUSTRY PLC**  
**STATEMENT OF CHANGES IN EQUITY (Unaudited)**  
For the period from 1 July 2024 to 31 March 2025


Amount in Taka

Particulars	Paid up Capital	Tax Holiday Reserve	FVOCI Reserve	Retained Earnings	Total
<b>Balance as at 1 July 2023</b>	312,436,270	4,392,110	(2,266,352)	2,700,165,629	3,014,727,658
Statement of profit or loss and other Comprehensive Income for period ended 30 June 2024			(6,344,369)	655,067,965	648,723,597
Dividend for the year 30 June, 2023 (Cash-60%)				(187,461,762)	(187,461,762)
<b>Balance as at 30 June 2024</b>	312,436,270	4,392,110	(8,610,721)	3,167,771,832	3,475,989,493
Statement of profit or loss and other Comprehensive Income for period ended 31 March 2025			(3,361,780)	521,572,088	518,210,308
Dividend for the year 30 June, 2024 (Cash-63%)				(196,834,850)	(196,834,850)
<b>Balance as at 31 March 2025</b>	312,436,270	4,392,110	(11,972,500)	3,492,509,070	3,797,364,950

**STATEMENT OF CHANGES IN EQUITY (Unaudited)**  
For the period from 1 July 2023 to 31 March 2024

Amount in Taka

Particulars	Paid up Capital	Tax Holiday Reserve	FVOCI Reserve	Retained Earnings	Total
<b>Balance as at 1 July 2022</b>	312,436,270	4,392,110	(685,588)	2,307,686,156	2,623,828,948
Statement of profit or loss and other Comprehensive Income for period ended 30 June 2023			(1,580,764)	579,941,235	578,360,472
Dividend for the period 30 June 2022 (Cash - 60%)				(187,461,762)	(187,461,762)
<b>Balance as at 30 June 2023</b>	312,436,270	4,392,110	(2,266,352)	2,700,165,629	3,014,727,658
Statement of profit or loss and other Comprehensive Income for period ended 31 March 2024			(4,838,816)	494,983,315	490,144,499
Dividend for the year 30 June 2023 (Cash-60%)				(187,461,762)	(187,461,762)
<b>Balance as at 31 March 2024</b>	312,436,270	4,392,110	(7,105,168)	3,007,687,182	3,317,410,395

  
Chief Financial Officer

  
Company Secretary

  
Director, Finance

Dated, Dhaka .  
28 April 2025


  
Managing Director

  
Chairman



**THE IBN SINA PHARMACEUTICAL INDUSTRY PLC**  
**STATEMENT OF CASH FLOWS (Unaudited)**  
For the period from 1 July 2024 to 31 March 2025

	Amount in Taka	
	01 July 2024 to 31 March 2025	01 July 2023 to 31 March 2024
<b>Cash Flows From Operating Activities:</b>		
Received from revenue and others	7,963,357,273	7,461,771,443
Payment for operation, expenses & others	(7,087,146,682)	(6,781,645,977)
Miscellaneous income	939,011	677,721
<b>Cash generated from operations</b>	<b>877,149,602</b>	<b>680,803,187</b>
Income tax paid	(115,444,950)	(115,840,028)
Payment for Financial charges	(56,685,494)	(33,060,710)
<b>Net cash provided by operating activities</b>	<b>705,019,158</b>	<b>531,902,448</b>
<b>Cash Flows From Investing Activities:</b>		
Acquisition of property, plant and equipment	(565,027,964)	(474,498,719)
Proceeds from sale of property, plant equipment	-	359,793
Investment in Subsidiary	(70,000,000)	(200,000,000)
Dividend Received/ IBBL-MPB	-	198,750
Acquisition of financial assets	70,544,340	(62,967,634)
Received from bank	400,400	203,415
<b>Net cash used in investing activities</b>	<b>(564,083,224)</b>	<b>(736,704,394)</b>
<b>Cash Flows From Financing Activities:</b>		
Payment of dividend	(178,147,838)	(154,173,401)
Payment of lease liabilities	(21,768,783)	(20,997,420)
Long term finance received/(paid) from bank (Net)	288,325,822	25,819,932
Short term finance received/(paid) from bank (Net)	(310,883,595)	453,395,505
<b>Net cash used in financing activities</b>	<b>(222,474,393)</b>	<b>304,044,616</b>
Increase/(decrease) in cash and cash equivalents	(81,538,459)	99,242,670
Cash and cash equivalents at 1 July	312,475,845	176,832,762
Foreign Exchange Fluctuation Gain/(Loss) on FCAD ERQ Accounts	1,039,444	1,576,458
<b>Cash and cash equivalents at 31 March</b>	<b>231,976,830</b>	<b>277,651,890</b>
<b>NOCFPS ( Note 32)</b>	<b>22.57</b>	<b>17.02</b>

  
Chief Financial Officer

  
Company Secretary

  
Director, Finance

Dated, Dhaka .  
28 April 2025

  
Managing Director

  
Chairman

**THE IBN SINA PHARMACEUTICAL INDUSTRY PLC**  
**SELECTED NOTES TO THE FINANCIAL STATEMENTS (UNAUDITED)**  
**For the period from 1 July 2024 to 31 March 2025**

**SELECTED EXPLANATORY NOTES:**

**1.1 The company and the group**

The IBN SINA Pharmaceutical Industry PLC (the "Company") was incorporated in Bangladesh on 22 December 1983 under the Companies Act, 1913 (replaced by the Companies Act 1994) and it was converted into a Public Limited Company in 1989.

The registered office of the company is at Tanin Center, 3 Asad Gate, Mirpur Road, Mohammadpur, Dhaka-1207. The Company is listed with Dhaka Stock Exchange Limited (DSE) and Chittagong Stock Exchange Limited (CSE).

As the 99.99% shareholder of The IBN SINA API Industry Ltd., 99.99% The IBN SINA Natural Medicine Ltd. and 65% The IBN SINA Polymer Industry Ltd.; The IBN SINA Pharmaceutical Industry PLC started its operation as a group company from 16 September 2019. Hereinafter it is referred as the group as and where applicable for the purpose of preparing consolidated financial statements.

**1.2 Nature of business**

The Company involves in production of pharmaceutical drugs and natural medicines and selling them in both local and international market.

**2 Basis of preparation**

**2.1 Statement of compliance**

These interim financial statements have been prepared in accordance with the International Accounting Standard IAS 34: Interim Financial Reporting, the Companies Act 1994, the Securities and Exchange Rules 2020, Financial Reporting Act 2015, relevant guidelines issued by Bangladesh Securities and Exchange Commission ("BSEC") and other applicable laws and regulations in Bangladesh.

The financial statements have been prepared on a historical cost basis, except for financial assets that have been measured at fair value where applicable. The financial statements provide comparative information in respect of the previous period and have been prepared on going concern basis. The interim financial statements should be read in conjunction with The IBN SINA Pharmaceutical Industry PLC's annual statutory financial statements as at 30 June 2024.

**2.2 Date of authorisation**

The interim financial statements were authorised for issue by the Board of Directors on 28 April 2025 for publication.

**2.3 Functional and presentation currency**

The financial statements are presented in Bangladeshi Taka (BDT), which is both functional and presentation currency of The IBN SINA Pharmaceutical Industry PLC.

**2.4 Significant accounting policies**

The same accounting policies and methods of computation have been followed in these interim financial statements as were applied in the preparation of the audited financial statements of The IBN SINA Pharmaceutical Industry PLC as at and for the year ended 30 June 2024.

**3 Significant Deviations**

**3.1 EARNINGS PER SHARE (EPS):**

Earnings per share has been calculated based on number of shares outstanding for the period ended 31 March 2025 and profit for the same period. The number of shares outstanding for the period was 31,243,627. Earnings per share for the corresponding period of 2024 has also been calculated based on 31,243,627 shares. No diluted earnings per share is required to be calculated as there was no scope for dilution during the period under review.

**3.2 SUBSEQUENT EVENTS:**

No material events occurred after the reporting date, non disclosure of which could affect the stakeholders to make proper valuation and decision.



**3.3 INCREASE IN EARNINGS PER SHARE (EPS):**

As a result of increase in sales revenue and profit , EPS has been increased during current period over last reporting period.

**3.4 INCREASE IN COST OF METRIALS:**

Cost of metrials increase due to increase in dollar rate against Bangladesh Taka.

**3.5 INCOME TAX:**

Payment of income tax increased due to increase in revenue and net profit. Advance income tax also increased due to payment for quarterly installment.

**3.6 PAYMENT FOR FIXED ASSETS:**

Payment for purchases of fixed assets increased due to increase in addition of fixed assets during this reporting period.

**3.7 Other income increased during the period due to increase in revenue from toll production charge and increased in foreign exchange fluctuation gain on FCAD ERQ Accounts .**

**3.8 Payment of dividend increased due to amount paid share holders during the reporting period.**

**3.9 FINANCE CHARGE:**

Finance charge during the reporting period increased due to increase of long term loan.

**3.10 INCREASE IN REVENUE:**

The main objective of the company is to increase revenue which is essential for survival in the market. Due to increase in demand for the company's product in market, revenue has been increased during current period over last reporting period.

**3.11 CASH FLOWS FROM INVESTING ACTIVITIES:**

Cash flows from investing activities increased during the reporting period due to increased payment made for purchase of fixed assets and payment of share capital of The IBN SINA API Industry Ltd. than the same period of last year.

**3.12 SHORT TERM FINANCE:**

Short term finance decreased during the period due to transferred long term finance.

**3.13 INCREASE IN NET OPERATING CASH FLOW PER SHARE (NOCFPS):**

Net operating cash flow per share (NOCFPS) increased during current period over last reporting period due to decrease in payment for cost & expenses & others.

**3.14 Previous period figures have been re-arranged to conform to current period presentation, where considered necessary.**

**04. PROPERTY, PLANT AND EQUIPMENT:****Cost :**

	31 March 2025	30 June 2024
Opening balance	3,956,915,644	3,671,727,462
Addition during the period	59,339,318	286,202,084
Disposal/Adjustment during the period	(1,851,770)	(1,013,902)
<b>Closing balance</b>	<b>4,014,403,192</b>	<b>3,956,915,644</b>
<b>Accumulated Depreciation:</b>		
Opening balance	1,554,782,910	1,377,611,748
Charged during the period	129,187,174	178,122,358
Disposal/Adjustment during the period	(1,148,230)	(951,195)
<b>Closing balance</b>	<b>1,682,821,854</b>	<b>1,554,782,910</b>
<b>Closing balance of Written Down Value (WDV)</b>	<b>2,331,581,338</b>	<b>2,402,132,734</b>

The factory land and land development (803 decimal) and building are pledged as security for long term and short term bank finance of the company.

**04 A. CONSOLIDATED PROPERTY, PLANT AND EQUIPMENT:**

The IBN SINA Pharmaceutical Industry PLC	2,331,581,338	2,402,132,734
The IBN SINA API Industry Ltd.	146,276,820	146,098,539
The IBN SINA Polymer Industry Ltd.	2,143,152	-
The IBN SINA Natural Medicine Ltd.	79,685,479	80,566,807
	<b>2,559,686,790</b>	<b>2,628,798,080</b>

**05. CAPITAL WORK-IN-PROGRESS:****A) Construction work-in-progress (Building)**

Opening balance	366,379,612	131,190,647
Addition during the period	296,452,068	366,379,612
Less: Transferred to property plant and equipment	-	(131,190,647)
<b>Closing balance</b>	<b>662,831,680</b>	<b>366,379,612</b>

**B) Machinery in transit and installation**

Opening balance	213,664,954	121,548,825
Addition during the period	298,052,538	274,985,002
Less: Transferred to property, plant and equipment	(88,815,961)	(182,868,873)
<b>Closing balance</b>	<b>422,901,531</b>	<b>213,664,954</b>
	<b>1,085,733,211</b>	<b>580,044,566</b>

i) Some new construction is under process to increase the overall production capacity of The IBN SINA Pharmaceutical Industry PLC. The amount in machinery in transit represents the amount for opening the LC for the procurement of Factory machineries for newly constructed factory building and increasing production capacity of existing factory which are not received yet by the company.

**05.A CONSOLIDATED CAPITAL WORK-IN-PROGRESS:****A) Construction work-in-progress (Building)**

Opening balance	465,469,776	198,768,487
Addition during the period	235,546,470	397,891,936
Less: Transferred to property plant and equipment	-	(131,190,647)
<b>Closing balance</b>	<b>701,016,246</b>	<b>465,469,776</b>

**B) Machinery in transit and installation**

Opening balance	673,427,435	373,701,080
Addition during the period	511,532,946	482,595,228
Less: Transferred to property, plant and equipment	(88,815,961)	(182,868,873)
<b>Closing balance</b>	<b>1,096,144,420</b>	<b>673,427,435</b>
	<b>1,797,160,666</b>	<b>1,138,897,211</b>



		Amount in Taka	
		31 March 2025	30 June 2024
<b>05.B RIGHT-OF-USE ASSETS:</b>			
Opening balance		130,252,602	130,252,602
Addition during the period		-	-
Disposal/Adjustment during the period		-	-
<b>Closing balance</b>		<b>130,252,602</b>	<b>130,252,602</b>
<b>Accumulated Depreciation:</b>			
Opening balance		72,375,357	47,385,679
Addition during the period		18,603,400	24,989,678
Disposal/Adjustment during the period		-	-
<b>Closing balance</b>		<b>90,978,757</b>	<b>72,375,357</b>
<b>Closing balance of Written Down Value (WDV)</b>		<b>39,273,845</b>	<b>57,877,245</b>
<b>06. FINANCIAL ASSETS (NON-CURRENT PORTION):</b>			
Exim Bank PLC		2,508,000	3,154,000
First Security Islami Bank PLC		9,434,600	12,531,750
Shahjalal Islami Bank PLC		1,854,000	1,843,700
Al-Arafah Islami Bank PLC		2,541,525	2,552,340
Social Islami Bank PLC		1,753,794	1,267,594
Islami Bank Bangladesh Ltd. (IBBL) in MPB		3,534,300	3,821,175
		<b>21,626,219</b>	<b>25,170,559</b>
The above investment in marketable securities are designated as Fair Value through Other Comprehensive Income (FVOCI) by the management. These are measured at fair value and presented as non-current asset. Unrealized gain/(loss) from the above investment were recognized in other comprehensive income. The shares of Exim Bank PLC and IBBP-MPB are listed in Dhaka Stock Exchange Ltd. and Chittagong Stock Exchange Ltd. The whole investment in shares of both the companies are in DSE only.			
<b>06.A CONSOLIDATED FINANCIAL ASSETS (NON-CURRENT PORTION):</b>			
Exim Bank PLC		2,508,000	3,154,000
First Security Islami Bank PLC		9,434,600	12,531,750
Shahjalal Islami Bank PLC		1,854,000	1,843,700
Al-Arafa Islami Bank PLC		2,541,525	2,552,340
Social Islami Bank PLC		1,753,794	1,267,594
Islami Bank Bangladesh PLC (IBBP) in MPB		3,534,300	3,821,175
Investment in API Industrial Park Services Ltd.		29,000,000	29,000,000
		<b>50,626,219</b>	<b>54,170,559</b>
<b>07 INVESTMENT IN SUBSIDIARIES :</b>			
The IBN SINA API Industry Ltd.		619,999,800	549,999,800
The IBN SINA Natural Medicine Ltd.		238,169,670	238,169,670
The IBN SINA Polymer Industry Ltd.		130,000,000	65,000,000
		<b>988,169,470</b>	<b>853,169,470</b>
i) The IBN SINA API Industry Ltd. is a 99.99% owned subsidiary company. Tk.7 crore have been paid as a part of share capital.			
ii) The IBN SINA Natural Medicine Ltd. is a 99.99% owned subsidiary company.			
iii) The IBN SINA Polymer Industry Ltd. is a 65% owned subsidiary company. Tk. 6.5 crore will be paid as a part of share capital which has been decided in the Board meeting.			
<b>07.A FINANCIAL ASSETS (CURRENT PORTION):</b>			
Opening Balance		89,500,000	22,500,000
During the period		(67,000,000)	67,000,000
Investment in Mudaraba Term Deposit		<b>22,500,000</b>	<b>89,500,000</b>
<b>07.B CONSOLIDATED FINANCIAL ASSETS (CURRENT PORTION):</b>			
Opening Balance		166,791,561	95,786,254
During the period		(144,291,561)	71,005,307
Investment in Mudaraba Term Deposit		<b>22,500,000</b>	<b>166,791,561</b>

	Amount in Taka	
	31 March 2025	30 June 2024
<b>08. INVENTORIES:</b>		
Raw materials	471,051,352	447,551,352
Packing materials	175,061,336	149,636,336
Work-in-process	132,991,974	103,450,764
Finished goods	386,044,770	356,044,770
Physicians' samples	4,965,192	4,821,092
Pad & literature	4,521,899	4,358,886
Spares & stores	402,685	372,575
Indirect materials	481,448	476,104
Printing & stationery	417,348	403,708
Laboratory chemicals	249,026	247,558
Material in transit	300,471,880	271,414,689
	<b>1,476,658,910</b>	<b>1,338,777,834</b>

- i) The inventory quantity can not be disclosed as some of material contain in liter, some are in pieces , some are in box and some are in kg, gram, mili gram, ton, liter and pcs as such quantity can not be inserted.
- ii) There is no damage goods or slow moving item in the inventory list.
- iii) As part of loan condition all of the company's inventory are pledged as security for loan finance of the company.
- iv) Inventory for raw materials , packing materials, Work In Process, Finished goods and material in transit increased during the period for ensuring smooth supply of goods to meetup increased customer demand.

<b>08.A CONSOLIDATED INVENTORIES:</b>		
Raw materials	577,849,573	593,235,375
Packing materials	210,741,763	194,418,191
Work-in-process	145,087,821	114,219,828
Finished goods	448,952,235	398,534,726
Physicians' samples	13,960,143	7,669,314
Pad & literature	4,521,899	4,358,886
Spares & stores	402,685	372,575
Indirect materials	481,448	476,104
Printing & stationery	417,348	403,708
Laboratory chemicals	249,026	247,558
Material in transit	300,471,880	271,414,689
	<b>1,703,135,821</b>	<b>1,585,350,954</b>

<b>09. TRADE AND OTHER RECEIVABLES:</b>		
Trade receivable (net off bad debt provision)	196,158,100	160,620,563
Receivable from provident fund (PF)	-	399,752
Dividend receivable	-	1,869,684
Profit receivable from MTD	1,776,249	3,764,794
Other receivable-toll charge	1,919,393	653,915
	<b>199,853,742</b>	<b>167,308,708</b>

- i) Amount are receivables from customers mainly different hospitals, medical colleges, clinics, diagnostic centers. No amount was due by the directors (including the Managing Director), managers and other officers of the company or any of them either severally or jointly with any other person.
- ii) Other receivable increased during the period as all bill except last month toll charge bill have been received.
- iii) Trade receivable increased during the period due to increase in sales revenue and customer types.

<b>09.A CONSOLIDATED TRADE AND OTHER RECEIVABLES:</b>		
Trade receivable (net off bad debt provision)	210,804,706	195,825,855
Receivable from provident fund (PF)	-	399,752
Dividend receivable	-	1,869,684
Inter-Company Receivables	25,000,000	-
Profit receivable from MTD	1,776,249	3,764,794
Other receivable-toll charge	1,919,393	653,915
	<b>239,500,348</b>	<b>202,514,000</b>



		Amount in Taka	
		31 March 2025	30 June 2024
<b>10. ADVANCES, DEPOSITS and PREPAYMENTS :</b>			
<b>a. Advances against</b>			
Salary	6,120,458	6,068,335	
Expenses/works/others	11,051,415	11,010,215	
Depot rent	7,007,487	7,407,181	
Motor cycles-to employees	9,182,183	8,736,752	
Others	745,298	706,533	
	<b>34,106,841</b>	<b>33,929,016</b>	
<b>b. Income tax</b>			
Opening balance	200,028,807	165,887,969	
Addition	115,444,950	188,898,585	
Adjusted during the period	-	(154,757,747)	
	<b>315,473,758</b>	<b>200,028,807</b>	
<b>c. Deposits</b>			
Security money	25,999,984	17,065,542	
<b>d. Pre payments</b>			
Value Added Tax	247	140	
	<b>375,580,830</b>	<b>251,023,506</b>	
<b>10.1 MATURITY ANALYSIS:</b>			
Realizable/adjustable within one year.	363,919,830	242,225,497	
Realizable/adjustable after one year.	11,661,000	8,798,009	
	<b>375,580,830</b>	<b>251,023,506</b>	
<b>10.A CONSOLIDATED ADVANCES, DEPOSITS AND PREPAYMENTS :</b>			
<b>a. Advances against</b>			
Salary	11,659,271	9,991,335	
Expenses/works/others	26,137,743	14,866,965	
Depot rent	7,007,487	7,407,181	
Motor cycles-to employees	29,134,288	33,774,284	
Others	1,528,880	1,843,151	
	<b>75,467,670</b>	<b>67,882,916</b>	
<b>b. Income tax</b>			
Opening balance	223,481,751	174,659,013	
Addition	120,126,130	203,580,485	
Adjusted during the period	-	(154,757,747)	
	<b>343,607,881</b>	<b>223,481,751</b>	
<b>c. Deposits</b>			
Security money	26,804,681	18,120,239	
<b>d. Pre payments</b>			
Value Added Tax	247	140	
	<b>445,880,479</b>	<b>309,485,047</b>	
The company did not give any advance, deposit and prepayment to the director's of the company, subsidiaries and other connected parties and employees advances are realised in normal course of business.			
<b>10.A.1 MATURITY ANALYSIS:</b>			
Realizable/adjustable within one year.	433,969,479	300,437,038	
Realizable/adjustable after one year.	11,911,000	9,048,009	
	<b>445,880,479</b>	<b>309,485,047</b>	
<b>11. CASH AND CASH EQUIVALENTS:</b>			
a. Cash in hand	5,802,643	6,553,245	
b. Cash at bank	222,639,187	302,422,600	
c. Imprest cash	3,535,000	3,500,000	
	<b>231,976,830</b>	<b>312,475,845</b>	

**11.A CONSOLIDATED CASH AND CASH EQUIVALENTS:**

- a. Cash in hand  
b. Cash at bank  
c. Imprest cash

Amount in Taka	
31 March 2025	30 June 2024
6,747,130	6,893,349
383,502,513	354,706,544
3,535,000	3,630,000
<b>393,784,643</b>	<b>365,229,893</b>

**12. SHARE CAPITAL:****Authorized:**

50,000,000 Ordinary Shares of Tk. 10 each

<b>500,000,000</b>	<b>500,000,000</b>
--------------------	--------------------

**Issued, Subscribed & Paid-Up :**

31,243,627 Ordinary Shares of Tk. 10 each fully paid up in cash

<b>312,436,270</b>	<b>312,436,270</b>
--------------------	--------------------

**The Shareholdings consist of :****Holders**

- Sponsors  
Institution (I.C.B)  
General Public

No. of Holders	Total Holdings	Percentage
1	13,843,312	44.31%
199	6,685,540	21.40%
12,285	10,714,775	34.29%
<b>12,485</b>	<b>31,243,627</b>	<b>100.00%</b>

The distribution schedule showing the number of share holders and their share holdings as on 27.03.2025 are as follows:

**Range of Holdings**

- Less than 500 shares  
500 to 5,000 shares  
5,001 to 10,000 shares  
10,001 to 20,000 shares  
20,001 to 30,000 shares  
30,001 to 40,000 shares  
40,001 to 50,000 shares  
Above 50,000 shares

No. of Holders	Total Holdings	Percentage
9,756	1,763,290	5.64%
2,334	3,500,983	11.21%
189	1,404,670	4.50%
105	1,435,151	4.59%
31	737,986	2.36%
17	586,009	1.88%
10	457,896	1.47%
43	21,357,642	68.36%
<b>12,485</b>	<b>31,243,627</b>	<b>100.00%</b>

The shares are listed with the Dhaka Stock Exchange Limited and Chittagong Stock Exchange Limited. The shares were quoted at Tk.287.7 in the Dhaka Stock Exchange Limited on 27.03.2025 and at Tk.285.5 in the Chittagong Stock Exchange Limited on 27.03.2025 respectively.

**13. TAX HOLIDAY RESERVE:**

This represents provision made out of profit of Tax Holiday period in accordance with Income Tax Ordinance 2023.

<b>4,392,110</b>	<b>4,392,110</b>
------------------	------------------

**14. FAIR VALUE THROUGH OTHER COMPREHENSIVE INCOME (FVOCI) RESERVE:**

- Closing market value of marketable securities  
Less: Cost of marketable securities  
**Unrealized gain before adjustment of deferred tax**  
Less: Deferred tax on unrealized gain/(loss)  
**Net unrealized gain/(loss) on marketable securities**

21,626,219	25,170,559
34,928,997	34,738,026
<b>(13,302,777)</b>	<b>(9,567,467)</b>
1,330,278	956,747
<b>(11,972,500)</b>	<b>(8,610,720)</b>

**15. RETAINED EARNINGS:**

- Opening Balance  
Dividend paid  
Add : Net profit during the period

3,167,771,833	2,700,165,629
(196,834,850)	(187,461,762)
521,572,088	655,067,965
<b>3,492,509,070</b>	<b>3,167,771,833</b>

**15A. CONSOLIDATED RETAINED EARNINGS:**

- Opening Balance  
Dividend paid  
Add: Net profit during the period

3,189,263,114	2,706,202,754
(196,834,850)	(187,461,762)
468,979,451	670,522,122
<b>3,461,407,715</b>	<b>3,189,263,114</b>

**15B. NON CONTROLLING INTERESTS:**

- The IBN SINA API Industry Ltd.  
The IBN SINA Natural Medicine Ltd.  
The IBN SINA Polymer Industry Ltd. (Paid by IBN SINA Trust)  
Add: Share of Profit/(Loss)

200	200
3,000	3,000
70,000,000	35,000,000
1,263,663	876,519
<b>71,266,863</b>	<b>35,879,719</b>



		Amount in Taka	
		31 March 2025	30 June 2024
<b>16. LONG TERM FINANCE :</b>			
i) From Al-Arafah Islamic Bank PLC Secured (Under Hire Purchase Shirkatul Melk-HPSM)		543,419,048	471,309,764
ii) Pubali Bank PLC (Long Term -H.P.S.M) Pharma		200,641,096	-
<b>Current maturity transferred to current liability</b>			
From Al-Arafah Islami Bank PLC Secured (Under Hire Purchase Shirkatul Mulk)	Note -21	(46,726,327)	(62,301,769)
<b>LONG TERM FINANCE - net off current maturity</b>		<b>697,333,817</b>	<b>409,007,995</b>
i) Loan amount represent the amounts which would be due for repayment after 12 (twelve) months from the date of Statement of Financial Position @ 15% profit from AIBP and 13% from Puabali Bank PLC.			
ii) The loan was taken from Al-Arafah Islami Bank PLC against mortgage of 803 decimal land and 63,811 square feet factory building located at Shafipur, Gazipur to import capital machinery and motor vehicle under Hire Purchase Shirkatul Melk.			
iii) HPSM is repayable in 84 monthly equal installment.			
iv) Currently all of the company's HPSM and other loans are classified as standard by the Bank.			
v) Information regarding loan fall due after five years.			
vi) The loan was			
vi) The loan was taken from Pubali Bank PLC against mortgage of land and under construction building located at Kaliakor, Gazipur. for building construction and import capital machinery under Hire Purchase Shirkatul Melk.			
Loan fall due from 2 to 5 years		362,279,365	314,206,509
Loan fall due from 6 to more years		335,054,452	94,801,486
		<b>697,333,817</b>	<b>409,007,995</b>
<b>16.A CONSOLIDATED LONG TERM FINANCE :</b>			
The IBN SINA Pharmaceutical Industry PLC		697,333,817	409,007,995
The IBN SINA API Industry Ltd.		223,975,055	121,482,527
		<b>921,308,872</b>	<b>530,490,522</b>
<b>17. EMPLOYEE BENEFIT OBLIGATIONS:</b>			
Opening Balance		1,185,180	1,005,406
Provision during the period		84,271,407	168,958,901
Less: Paid during the period		(83,914,594)	(168,779,126)
		<b>1,541,993</b>	<b>1,185,180</b>
<b>17. A CONSOLIDATED EMPLOYEE BENEFIT OBLIGATIONS:</b>			
Opening Balance		1,185,180	1,005,406
Provision during the period		106,138,596	208,717,427
Less: Paid during the period		(105,781,783)	(208,537,652)
		<b>1,541,993</b>	<b>1,185,180</b>
<b>17. B LEASE LIABILITIES:</b>			
Opening Balance		50,336,979	73,750,975
Finance charge		2,987,876	5,810,264
Paid during the period		(21,768,783)	(29,224,260)
<b>Closing balance</b>		<b>31,556,072</b>	<b>50,336,979</b>
Less : Transferred to current maturity		(16,840,388)	(25,538,281)
		<b>14,715,684</b>	<b>24,798,698</b>
i) The company has lease against its head office and its training center located at Mohammadpur, Dhaka.			
ii) Lease period is upto 31.10.2026			
iii) Monthly rental payment is Tk. 1,851,270			
iv) Advance amount paid Tk. 11,661,000			
v) Monthly advance adjustment Tk. 50,000			

## Amount in Taka

31 March 2025

30 June 2024

## 18. DEFERRED TAX LIABILITY:

Deferred tax assets and liabilities have been recognized and measured in accordance with the provisions of IAS 12 Income Taxes. Related deferred tax expense/(income) have been disclosed in note 19. The components of deferred tax assets and liabilities are given below:

Particulars	Carrying amount	Tax base value	Taxable (deductible) temporary difference	Applicable tax rate	Deferred tax liability
Property, plant and equipment	2,331,581,338	1,757,016,075	574,565,263	20.00%	114,913,053
Gratuity	85,456,588	83,914,594	(1,541,994)	20.00%	(308,399)
Lease	24,558,161	13,244,333	11,313,827	20.00%	2,262,765
Unrealized gain on marketable securities	(13,302,777)	-	(13,302,777)	10.00%	(1,330,278)
<b>As at 31 March 2025</b>	<b>2,428,293,309</b>	<b>1,854,175,002</b>	<b>571,034,319</b>		<b>115,537,142</b>
Property, plant and equipment	2,402,132,734	1,891,921,442	510,211,292	20.00%	102,042,258
Gratuity	169,964,307	168,779,126	(1,185,181)	20.00%	(237,036)
Lease	7,540,266	13,994,333	(6,454,067)	20.00%	(1,290,813)
Unrealized gain on marketable securities	(9,567,467)	-	(9,567,467)	10.00%	(956,747)
Bad Debt provision	1,359,800	-	(1,359,800)	20.00%	(271,960)
<b>As at 30 June 2024</b>	<b>2,571,429,640</b>	<b>2,074,694,901</b>	<b>491,644,778</b>		<b>99,285,702</b>

## DEFERRED TAX EXPENSES/(INCOME) :

Closing balance of deferred tax liability	115,537,142	99,285,702
Opening balance of deferred tax liability	99,285,702	105,154,476
<b>Total deferred tax expenses/(income)</b>	<b>16,251,439</b>	<b>(5,868,773)</b>
Less: Deferred tax (income)/ expenses related to other comprehensive income	(373,531)	704,930
	<b>15,877,908</b>	<b>(5,163,844)</b>

## 19 CONSOLIDATED DEFERRED TAX LIABILITY:

Particulars	Carrying amount	Tax base value	Taxable (deductible) temporary difference	Applicable tax rate	Deferred tax liability
Property, plant and equipment	2,557,543,637	1,974,062,249	583,481,388	20% to 25%	117,195,644
Gratuity	107,323,777	105,781,783	(1,541,994)		(308,399)
Lease	24,005,826	13,244,333	10,761,492	10.00%	2,095,640
Unrealized gain on marketable securities	(13,302,777)	-	(13,302,777)		(1,330,278)
<b>As at 31 March 2025</b>	<b>2,675,570,462</b>	<b>2,093,088,365</b>	<b>579,398,109</b>		<b>117,652,608</b>
Property, plant and equipment	2,628,798,080	2,111,901,346	516,896,734	20% to 27.50%	103,762,047
Gratuity	209,722,833	208,537,652	(1,185,181)		(237,036)
Accrued profit on mtdr	1,113,777	-	1,113,777	10.00%	306,289
Lease	7,237,421	13,994,333	(6,756,912)		(1,374,195)
Unrealized gain on marketable securities	(9,567,467)	-	(9,567,467)	10.00%	(956,747)
Bad Debt provision	1,635,117	100,000	(1,535,117)		(320,172)
<b>As at 30 June 2024</b>	<b>2,838,939,761</b>	<b>2,334,533,331</b>	<b>498,965,835</b>		<b>101,180,185</b>

## CONSOLIDATED DEFERRED TAX EXPENSES/(INCOME) :

Closing balance of deferred tax liability	117,652,608	101,180,185
Opening balance of deferred tax liability	101,180,185	105,813,064
<b>Total deferred tax expenses/(income)</b>	<b>16,472,422</b>	<b>(4,632,878)</b>
Less: Deferred tax (income)/ expenses related to other comprehensive income	(373,531)	704,930
	<b>16,098,891</b>	<b>(3,927,948)</b>

## 20. SHORT TERM FINANCE :

A. From Al-Arafah Islami Bank PLC - Secured (Under Composite facilities LC(MPI/TR)	826,862,322	1,122,170,475
	<b>826,862,322</b>	<b>1,122,170,475</b>

i) Loan amount represent the amounts which would be due for repayment within 12 (twelve) months from the date of Statement of Financial Position @ 15% of profit and 0.25% commission per quarter to be paid.

ii) The loan was taken from Al-Arafah Islami Bank Ltd. against mortgage of 803 decimal land and 63,811 square feet factory building located at Shafipur, Gazipur to import Pharmaceuticals raw materials, imported goods and to purchase business items from local market under Composite facilities LC/MPI/MPI TR/UPAS/ Baimuajjal agreement.

iii) Short term loan is repayable with in twelve months.

iv) Currently all of the company's MPI/UPAS and other loans are classified as standard by the Bank.



		Amount in Taka	
		31 March 2025	30 June 2024
<b>20.A CONSOLIDATED SHORT TERM FINANCE :</b>			
A. The IBN SINA Pharmaceutical Industry PLC (Under Composite facilities LC(MPI/TR))		826,862,322	1,122,170,475
B. The IBN SINA API Industry Ltd.		18,000,001	120,383,444
		<u>844,862,323</u>	<u>1,242,553,919</u>
<b>21. CURRENT PORTION OF LONG TERM FINANCE:</b>			
i) From Al-Arafah Islami Bank PLC-Secured (Under Hire Purchase Shirkatul Melk)		<u>46,726,327</u>	<u>62,301,769</u>
The amounts represent current maturity of long term finance obtained from Al-Arafah Islami Bank PLC and lease liability which are repayable within next 12 (Twelve) months from the date of Statement of Financial Position.			
<b>22. TRADE AND OTHER PAYABLES:</b>			
Payable to suppliers		315,406,771	181,215,838
Inter-company payables (share capital for Polymer)		65,000,000	-
Provisions	Note-22.1	156,704,610	144,607,133
Accrued expenses		204,226,491	183,670,820
Security money received from employees and others		11,108,078	9,569,964
Workers' profit participation fund & welfare fund		34,635,324	43,132,111
		<u>787,081,273</u>	<u>562,195,866</u>
<b>22.1 PROVISIONS:</b>			
Opening balance		144,607,133	102,620,654
Provisions made during the period		156,704,610	144,607,133
Provisions used during the period		(144,607,133)	(102,620,654)
Closing balance		<u>156,704,610</u>	<u>144,607,133</u>
<b>22.A CONSOLIDATED TRADE AND OTHER PAYABLES :</b>			
Payable to suppliers		524,328,933	260,299,854
Provisions		156,704,610	144,607,133
Accrued expenses		220,053,216	204,021,154
Security money received from employees and others		11,108,078	9,569,964
Workers' profit participation fund & welfare fund		34,635,324	45,486,240
		<u>946,830,160</u>	<u>663,984,345</u>
<b>22.B UNCLAIMED DIVIDEND :</b>			
Opening		39,140,597	31,578,229
Addition		196,834,850	187,461,762
Paid to share holders		(171,240,507)	(174,011,997)
Paid to Capital Market Stabilisation Fund		(6,907,331)	(5,887,397)
		<u>57,827,610</u>	<u>39,140,597</u>
<b>22.2 UNCLAIMED DIVIDEND :</b>			
Year-wise break-up of the above is as follows :			
2020-21		-	8,652,960
2021-22		13,440,246	15,909,874
2022-23		16,322,445	14,577,763
2023-24		28,064,919	-
		<u>57,827,610</u>	<u>39,140,597</u>
<b>23. INCOME TAX PAYABLES:</b>			
Opening balance		255,866,409	197,886,050
Current tax provision		155,256,480	212,738,107
		<u>411,122,889</u>	<u>410,624,156</u>
Adjusted during the year/period		-	(154,757,747)
		<u>411,122,889</u>	<u>255,866,409</u>
<b>23.A CONSOLIDATED INCOME TAX PAYABLES:</b>			
Opening balance		284,580,559	212,062,009
Current tax expense		161,131,828	227,276,297
		<u>445,712,387</u>	<u>439,338,306</u>
Adjusted during the year/period		-	(154,757,747)
		<u>445,712,387</u>	<u>284,580,559</u>

		Amount in Taka	
		1 July 2024 to 31 March 2025	1 July 2023 to 31 March 2024
<b>24. REVENUE:</b>			
Local revenue		7,859,985,361	7,293,789,974
Export revenue		135,916,946	155,091,948
		<u>7,995,902,307</u>	<u>7,448,881,922</u>
<b>24.A CONSOLIDATED REVENUE:</b>			
The IBN SINA Pharmaceutical Industry PLC		7,995,902,307	7,448,881,922
The IBN SINA Natural Medicine Ltd.		817,485,496	930,984,376
		<u>8,813,387,803</u>	<u>8,379,866,298</u>
<b>24.B COST OF GOODS SOLD :</b>			
Materials		3,801,299,311	3,665,014,795
Factory Overhead		888,702,826	707,467,493
Depreciation		103,669,340	104,943,880
		<u>4,793,671,477</u>	<u>4,477,426,167</u>
<b>24.C CONSOLIDATED COST OF GOODS SOLD :</b>			
Materials		4,160,481,014	4,094,358,929
Factory Overhead		1,011,171,670	821,186,008
Depreciation		108,778,139	110,205,556
		<u>5,280,430,823</u>	<u>5,025,750,492</u>
<b>25. ADMINISTRATIVE EXPENSES :</b>			
Salary, Wages & Allowances		97,654,318	83,133,571
Repairs & Maintenance		8,833,247	9,083,811
Travelling & Conveyance		3,858,716	3,835,663
AGM, Fees and Others		1,899,390	1,739,717
Depreciation		20,017,222	19,183,423
Other Expenses		41,839,305	36,122,530
		<u>174,102,198</u>	<u>153,098,715</u>
<b>25.A CONSOLIDATED ADMINISTRATIVE EXPENSES :</b>			
Salary, Wages & Allowances		115,148,592	98,094,389
Repairs & Maintenance		10,279,918	9,890,827
Travelling & Conveyance		3,866,806	3,837,873
AGM, Fees and Others		1,899,390	2,987,570
Research & Development		1,044,499	651,109
Depreciation		24,879,034	23,306,686
Other Expenses		48,479,926	38,540,195
		<u>205,598,166</u>	<u>177,308,649</u>
i) Salary, wages & allowance increased due to increase in manpower, gratuity payment.			
ii) Repairs & Maintenance expense increased due to increase in maintenance of fixed assets to meet business needs.			
iii) Travelling & conveyance increased during the period due to increase travel.			
iv) Research & development expense increased during this period due to meet business needs.			
iv) Depreciation expense during the reporting period increased due to addition of fixed assets .			
<b>26. SELLING &amp; DISTRIBUTION EXPENSES :</b>			
Salary, Wages & Allowances		1,366,192,807	1,191,276,745
Travelling & Conveyance		9,044,619	6,574,198
Market Survey & Research and Product development		5,442,691	5,664,597
Field personnel expenses		286,231,107	259,858,231
Sample, Literature & Promotional Expenses		172,488,246	162,175,099
Delivery Expenses		220,203,831	189,756,775
Depreciation		24,104,012	26,554,501
Other Expenses		202,587,846	301,513,689
		<u>2,286,295,158</u>	<u>2,143,373,835</u>
Less: Expenses for INM		(32,699,420)	(37,239,375)
		<u>2,253,595,738</u>	<u>2,106,134,460</u>



		Amount in Taka	
		1 July 2024 to 31 March 2025	1 July 2023 to 31 March 2024
<b>26.A CONSOLIDATED SELLING &amp; DISTRIBUTION EXPENSES :</b>			
Salary, Wages & Allowances		1,574,514,525	1,398,840,882
Travelling & Conveyance		10,667,569	8,137,051
Market Survey & Research and Product development		5,442,691	5,664,597
Field personnel expenses		342,652,792	310,006,309
Sample, Literature & Promotional Expenses		212,243,176	192,395,311
Delivery Expenses		220,203,831	189,756,775
Depreciation		24,455,223	26,891,649
Other Expenses		212,402,018	311,797,176
		<u>2,602,581,825</u>	<u>2,443,489,750</u>
i) Travelling & conveyance increased during the period due to increase travel.			
ii) Field personal and delivery expense during the reporting period increased due to increase in fuel and gas cost and vehicles rent cost.			
<b>27. WORKERS' P.P FUND &amp; WELFARE FUND :</b>		<u>34,635,324</u>	<u>32,623,562</u>
<b>27.A CONSOLIDATED WORKERS' P.P FUND &amp; WELFARE FUND :</b>			
The IBN SINA Pharmaceutical Industry PLC		34,635,324	32,623,562
The IBN SINA Natural Medicine Ltd.		-	1,603,378
		<u>34,635,324</u>	<u>34,226,940</u>
<b>28. INCOME TAX EXPENSES:</b>			
Current Tax		155,256,480	160,120,673
Deferred Tax income/(expense)		15,877,908	(2,632,746)
		<u>171,134,388</u>	<u>157,487,927</u>
<b>Reconciliation of Effective Tax Rate</b>			
<b>Types of income</b>	<b>Income</b>	<b>Effective Tax Rate</b>	<b>Tax</b>
Capital Gain	-	20.00%	-
Business Income	692,706,476	20.00%	138,541,295
	692,706,476	20.00%	138,541,295
Non Deductible Expenses		2.41%	16,715,185
Deferred Tax (income)/expense		2.29%	15,877,908
		<u>24.71%</u>	<u>171,134,388</u>
<b>28.A CONSOLIDATED INCOME TAX EXPENSES:</b>			
Current Tax		161,131,828	169,870,814
Deferred Tax income/(expense)		16,098,890	(1,912,426)
		<u>177,230,718</u>	<u>167,958,388</u>
<b>Reconciliation of Effective Tax Rate</b>			
<b>Types of income</b>	<b>Income</b>	<b>Effective Tax Rate</b>	<b>Tax</b>
Capital Gain	-	20.00%	-
Business Income	646,597,313	20% to 25%	146,822,454
	646,597,313	22.71%	146,822,454
Non Deductible Expenses		2.59%	16,715,185
Deferred Tax (income)/expense		2.46%	15,877,908
		<u>27.75%</u>	<u>179,415,547</u>
<b>29. CHANGE IN FAIR VALUE OF MARKETABLE SECURITIES :</b>			
Closing value of marketable securities		(13,302,777)	(7,894,631)
Opening value of marketable securities		(9,567,467)	(2,518,168)
		<u>(3,735,311)</u>	<u>(5,376,463)</u>
<b>30. EARNINGS PER SHARE (EPS) :</b>			
Basic earnings per share has been calculated as follows :			
Earnings attributable to the Ordinary Shareholders (Net profit after tax)		521,572,088	494,983,315
Divided by number of Ordinary Shares outstanding during the year/period		31,243,627	31,243,627
<b>EARNINGS PER SHARE (EPS)</b>		<u>16.69</u>	<u>15.84</u>

		Amount in Taka	
		1 July 2024 to 31 March 2025	1 July 2023 to 31 March 2024
<b>30.A CONSOLIDATED EARNINGS PER SHARE (EPS) :</b>			
Basic earnings per share has been calculated as follows :			
Earnings attributable to the Ordinary Shareholders (Net profit after tax)		469,366,595	507,155,091
Divided by number of Ordinary Shares outstanding during the year/period		31,243,627	31,243,627
<b>CONSOLIDATED EARNINGS PER SHARE (EPS) :</b>		<b>15.02</b>	<b>16.23</b>
<b>31. Net Assets Value Per Share (NAV)</b>			
Equity attributable to the owners of the company		3,797,364,950	3,475,989,493
Divided by weighed average number of Ordinary Shares outstanding during the period		31,243,627	31,243,627
<b>Net Assets Value Per Share (NAV)</b>		<b>121.54</b>	<b>111.25</b>
Net Assets Value Per Share (NAV) increased during the period due to increase in sales, maintaining stable expenses growth and increase in retained earning.			
<b>31.A Consolidated Net Assets Value Per Share (NAV):</b>			
Net Assets Value		3,766,263,595	3,497,480,774
Divided by weighed average number of Ordinary Shares outstanding during the period		31,243,627	31,243,627
<b>Consolidated Net Assets Value Per Share (NAV):</b>		<b>120.55</b>	<b>111.94</b>
<b>32. Net Operating Cash Flow Per Share (NOCFPS):</b>			
Net cash provided by operating activities		705,019,158	531,902,448
Divided by weighed average number of Ordinary Shares outstanding during the period		31,243,627	31,243,627
		<b>22.57</b>	<b>17.02</b>
<b>32.A Consolidated Net Operating Cash Flows Per Share (NOCFPS):</b>			
Net cash provided by operating activities		817,362,271	484,180,030
Divided by weighed average number of Ordinary Shares outstanding during the period		31,243,627	31,243,627
		<b>26.16</b>	<b>15.50</b>
<b>33. Reconciliation of net profit with cash flows from operating activities:</b>			
<b>Profit Before Tax (PBT)</b>		692,706,476	652,471,242
<b>Adjustment</b>			
Depreciation		147,790,574	150,681,804
Deferred Tax		16,251,439	(2,095,100)
Unrealized foreign exchange loss		(1,039,444)	(1,576,458)
Share of associate profit/Loss		1,776,249	2,516,033
Gain on sale of Motor Vehicles		-	359,793
Dividend received		1,869,684	696,251
Interest Income		(400,400)	(203,415)
<b>Change In operating assets</b>			
Increase in inventory		(137,881,076)	(147,417,072)
Increase in accounts receivables		(30,675,350)	13,585,772
Decrease in advances, deposits and prepayments		9,112,374	(572,535)
Increase/(decrease) in trade and other payable		177,282,262	11,961,616
Increase/(decrease) in retirement benefit obligation		356,813	395,256
Finance charge		(56,685,494)	(33,060,710)
Tax paid during the period		(115,444,950)	(115,840,028)
		<b>705,019,158</b>	<b>531,902,448</b>
<b>34. Finance Charge:</b>			
Finance charge for long term finance		56,685,494	33,060,710
Finance charge for lease		2,987,876	4,543,065
		<b>59,673,370</b>	<b>37,603,775</b>
<b>34.A Consolidated Finance Charge:</b>			
Finance charge for long term finance		56,685,494	33,060,710
Finance charge for lease		2,987,876	4,543,065
		<b>59,673,370</b>	<b>37,603,775</b>



35. RELATED PARTY DISCLOSURE:

Name of party	Relationship	Nature of transaction	Transaction		March 2025	June 2024
			Dr.	Cr.	Receivable/(Payable)	
The IBN SINA API Industry Ltd.	Subsidiary (99.99%)	Acquisition of share Capital		70,000,000	619,999,800	549,999,800
The IBN SINA Natural Medicine Ltd.	Subsidiary (99.99%)	Acquisition of share		-	238,169,670	238,169,670
		Administrative Expenses	-			
		Distribution Expense	32,699,420		-	
The IBN SINA Polymer Industry Ltd.	Subsidiary (65%)	Lease	270,000	-	270,000	-
		Acquisition of share Capital	65,000,000	65,000,000	130,000,000	65,000,000

35.01. NON-CONTROLLING INTEREST

The IBN SINA API Industry Ltd.  
The IBN SINA Natural Medicine Ltd.  
The IBN SINA Polymer Industry Ltd.

Profit Amount	NCI (%)	Net Amount
(15,822,750)	0.000050	(8)
(37,794,773)	0.001260	(476)
1,107,509	35.000000	387,628
(52,510,014)		387,144

  
Chief Financial Officer

  
Company Secretary

  
Director, Finance

Dated, Dhaka .  
28 April 2025

  
Managing Director

  
Chairman